Dr. Paramjit Tappia Joins BioMark Scientific Advisory Team
Vancouver, British Columbia – (September 19th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Paramjit Tappia to its scientific advisory team. Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Tappia into our scientific advisory team. His […]
BioMark Partners with Alberta Machine Intelligence Institute to Amplify Clinical Diagnostic Decision Making
Vancouver, British Columbia – (April 25, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to announce that it has penned a deal with the Alberta Machine Intelligence Institute (Amii) led by Dr. Osmar Zaïane of the University of Alberta’s Department of Computing Science and his team to assess and […]
BioMark Diagnostics – Sponsored Project Receives NSERC Engage Grant
Vancouver, British Columbia – (February 27th, 2018)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) announces the award of a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to partner with Donald Miller, Ph.D., Professor, Department of Pharmacology and Therapeutics at the University of Manitoba, to fabricate new nanomaterial and focus […]
BioMark’s Health Canada Submission Update
Vancouver, British Columbia – (February 21st, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide an update on its Health Canada submission progress following data analysis on its clinical trial activities. Listed below are new accomplishments over the past 2 weeks: BioMark’s regulatory team at St. Boniface Hospital […]
AI early diagnosis could save heart and cancer patients
AI early diagnosis could save heart and cancer patients By Pallab GhoshScience correspondent, BBC News2 January 2018 Original Article: http://www.bbc.com/news/health-42357257 Researchers at an Oxford hospital have developed artificial intelligence (AI) that can diagnose scans for heart disease and lung cancer. The systems will save billions of pounds by enabling the diseases to be picked up much earlier. The heart disease […]
Further Progress in BIOMARK’s Clinical Trial and Regulatory Review
Vancouver, British Columbia – (January 3rd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide further progress on its clinical trial activities as previously reported on November 1st, 2017. New accomplishments over the past few weeks are listed below. Samples from the outlier cohort have been received at […]
Global Affairs Canada Supports BioMark’s Trip to Japan
Vancouver, British Columbia – (December 19th, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is proud to announce that the Canadian Government’s established Going Global International (GGI) program has generously approved its second application to further engage with top tier Japanese institutions following its successful initial visit in June 2017. Based […]
Dr. Ian Smith Joins BioMark’s Board of Directors
Vancouver, British Columbia – (December 5th, 2017)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company. Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Smith to our board. His achievements in […]
BIOMARK’s Clinical Trial & Research Update
Vancouver, British Columbia – (November 1, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide the latest clinical trial update. The company analyzed samples from the clinical trials samples at a Good Laboratory Practice (GLP) facility, which utilized the Company’s internal standards (obtained under Health Canada’s Investigational Testing […]
BIOMARK ANNOUNCES PATENT GRANTED IN CHINA
Vancouver, British Columbia – (October 25th, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRASFERASE” has been prosecuted to allowance and issued in China. Rashid Ahmed, President and CEO, says, “Granting of this patent expands […]
